secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001558370-23-010139
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine names Erick Lucera as CFO, replacing Michelle Robertson
-----------------------------------------------------------------------

- Erick Lucera appointed EVP and CFO effective May 17, 2023, succeeding Michelle Robertson who stepped down May 16.
- Lucera previously CFO at AVEO Pharma; receives $470k base salary, 45% target bonus, and equity grants.
- Equity includes option for 155,800 shares, RSU for 77,900 shares, and performance-based PSU for 77,900 shares.
- Robertson will transition through Aug 16, 2023, receiving 12 months base salary and COBRA contributions.
- Robertson's vested stock option exercise period extended to Aug 16, 2024; release agreement required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/edit-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer